Scholarlink

<p>Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) poses a persistent clinical threat due to limited therapeutic options and the rapid emergence of resistance. Azeliragon, an orally bioavailable Receptor for Advanced Glycation End-products (RAGE) inhibitor previously tested in human trials, was identified as a potential antibacterial agent against MRSA through high-throughput screening. It exhibited potent antibacterial activity against clinical <i>S. aureus</i> isolates (MIC<sub>50</sub> = 6.25 μM/3.3 μg/mL) and significantly inhibited biofilm formation. Metabolomics and proteomics suggested perturbation of lipid pathways and potential interaction with MurA. Target validation using Drug Affinity Responsive Target Stability (DARTS), Determination of biomolecular affinity by bio-layer interferometry (BLI), Limited proteolysisemass spectrometry (LiP-MS), and site-directed mutagenesis provided biochemical evidence supporting MurA as an intracellular target. Whole Genome Sequencing of resistant derivatives revealed Single Nucleotide Polymorphisms (SNPs) in cell-wall and fatty-acid efflux regulators including <i>yycH</i>, <i>farE</i>/<i>farR</i>, consistent with membrane and cell-wall perturbation. In a murine wound model Azeliragon reduced local bacterial burden and accelerated healing to levels comparable with vancomycin. Azeliragon is a repurposable antibacterial agent that perturbs membrane phospholipid homeostasis and engages MurA-dependent peptidoglycan synthesis. These findings support further preclinical development of Azeliragon or optimized derivatives as potential therapeutics against MRSA and other gram-positive pathogens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Junhua Ma,
  • Yuqing Xia,
  • Jintuan Lin,
  • Chengchun Chen,
  • Qingyin Meng,
  • Zhijian Yu,
  • Lili Ouyang,
  • Bao Chai,
  • Bing Bai,
  • TieYing Hou,
  • Zewen Wen

摘要

Methicillin-resistant Staphylococcus aureus (MRSA) poses a persistent clinical threat due to limited therapeutic options and the rapid emergence of resistance. Azeliragon, an orally bioavailable Receptor for Advanced Glycation End-products (RAGE) inhibitor previously tested in human trials, was identified as a potential antibacterial agent against MRSA through high-throughput screening. It exhibited potent antibacterial activity against clinical S. aureus isolates (MIC50 = 6.25 μM/3.3 μg/mL) and significantly inhibited biofilm formation. Metabolomics and proteomics suggested perturbation of lipid pathways and potential interaction with MurA. Target validation using Drug Affinity Responsive Target Stability (DARTS), Determination of biomolecular affinity by bio-layer interferometry (BLI), Limited proteolysisemass spectrometry (LiP-MS), and site-directed mutagenesis provided biochemical evidence supporting MurA as an intracellular target. Whole Genome Sequencing of resistant derivatives revealed Single Nucleotide Polymorphisms (SNPs) in cell-wall and fatty-acid efflux regulators including yycH, farE/farR, consistent with membrane and cell-wall perturbation. In a murine wound model Azeliragon reduced local bacterial burden and accelerated healing to levels comparable with vancomycin. Azeliragon is a repurposable antibacterial agent that perturbs membrane phospholipid homeostasis and engages MurA-dependent peptidoglycan synthesis. These findings support further preclinical development of Azeliragon or optimized derivatives as potential therapeutics against MRSA and other gram-positive pathogens.